Magle Chemoswed Holding AB

MAGLE

SE0014401014

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 11:24:00 2024-05-10 am EDT			5-day change	1st Jan Change
32 ^SEK	0.00%		0.00%	+26.98%

Apr. 18	Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 22	Magle Chemoswed Holding AB Resolves to Withdraws Dividend Proposal for the Year 2023	CI

Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022

February 16, 2023 at 02:00 am EST

Magle Chemoswed Holding AB (publ) reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported sales was SEK 46.05 million compared to SEK 35.99 million a year ago. Revenue was SEK 48.84 million compared to SEK 39.39 million a year ago.

Net income was SEK 0.841 million compared to SEK 1.2 million a year ago. Basic earnings per share from continuing operations was SEK 0.08 compared to SEK 0.11 a year ago. Diluted earnings per share from continuing operations was SEK 0.08 compared to SEK 0.11 a year ago.

Latest news about Magle Chemoswed Holding AB

Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 18	CI
Magle Chemoswed Holding AB Resolves to Withdraws Dividend Proposal for the Year 2023	Mar. 22	CI
Magle Chemoswed Holding AB (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million.	Mar. 21	CI
Magle Chemoswed Holding AB Proposes Dividend for the Fiscal Year 2023	Feb. 16	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 16	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 16	CI
Magle Group Enters Collaboration with Sirtex Medical to Support the International Commercialization of Embocept S Dsm 50 Um	23-09-08	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-29	CI
Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-29	CI
Magle Group Announces Positive Results from Post-Market Clinical Follow-Up of SmartPAN	23-04-27	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-16	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-16	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-16	CI
Magle Chemoswed Holding AB 's Proprietary Product Axxo® Woundgel Receives Regulatory Approval in Kuwait	22-11-21	CI
Magle Group's Vascular Embolic Product Embocept® S Receives Regulatory Approval in Argentina	22-11-17	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-29	CI
Magle Appoints New Chief Marketing/Innovation Officer	22-09-12	MT
Magle Group Appoints Helena Ossmer Thedius as New Chief Marketing and Innovation Officer	22-09-12	CI
Magle Chemoswed Holding AB Announces the Resignation of Julia Kamber Rouhi from the Board of Directors of Magle Chemoswed Holding	22-08-16	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-07-29	CI
Magle Group Announces First Patients Enrolled in a Post-Market Study of Medical Device SmartPAN®	22-07-11	CI
Magle Chemoswed Holding AB Announces Post Market Clinical Study for SmartPAN®	22-05-13	CI
Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-25	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-25	CI

Chart Magle Chemoswed Holding AB

Duration

Period

More charts

Company Profile

Magle Chemoswed Holding AB is a Sweden-based company that conducts research, development and manufacturing in the fields of pharmaceutical chemistry and pharmaceutical technology. The Company's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.

Sector

Pharmaceuticals

Calendar

2024-07-17 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Magle Chemoswed Holding AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MAGLE CHEMOSWED HOLDING AB	+26.98%	31.89M
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals